Aerojet Rocketdyne Holdings, Inc. Reports 2016 Fourth Quarter and Annual Results
Mar 01, 2017 21:02 pm UTC| Business
EL SEGUNDO, Calif., March 01, 2017 -- Aerojet Rocketdyne Holdings, Inc. (NYSE:AJRD) today reported results for the fourth quarter and year ended December 31, 2016. Financial Overview Fourth Quarter of Fiscal 2016...
Aerojet Rocketdyne Holdings, Inc. Reports 2016 Fourth Quarter and Annual Results
Mar 01, 2017 21:02 pm UTC| Business
EL SEGUNDO, Calif., March 01, 2017 -- Aerojet Rocketdyne Holdings, Inc. (NYSE:AJRD) today reported results for the fourth quarter and year ended December 31, 2016. Financial Overview Fourth Quarter of Fiscal 2016...
Mar 01, 2017 21:02 pm UTC| Business
Phase 3 trial of sparsentan in FSGS to initiate in second half of 2017; Interim analysis of proteinuria to serve as basis for NDA filing for accelerated approval Full year 2016 revenue grew 34% over 2015 to $134 million ...
Mar 01, 2017 21:02 pm UTC| Business
Phase 3 trial of sparsentan in FSGS to initiate in second half of 2017; Interim analysis of proteinuria to serve as basis for NDA filing for accelerated approval Full year 2016 revenue grew 34% over 2015 to $134 million ...
Mar 01, 2017 21:02 pm UTC| Business
Record 2016 Revenue of $184.5 million, up 76% YOYRecord Full Year 2016 Diluted Earnings per Share of $0.57, up 613% YOYRecord Full Year 2016 Adjusted Earnings per Share of $1.12, up 315% YOYRecord Policies in force totaled...
Mar 01, 2017 21:02 pm UTC| Business
Record 2016 Revenue of $184.5 million, up 76% YOYRecord Full Year 2016 Diluted Earnings per Share of $0.57, up 613% YOYRecord Full Year 2016 Adjusted Earnings per Share of $1.12, up 315% YOYRecord Policies in force totaled...
Fate Therapeutics to Present at Two Upcoming Conferences in March
Mar 01, 2017 21:02 pm UTC| Business
SAN DIEGO, March 01, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today...
U.S. Appeals Court Allows Trump Administration to Enforce Medicaid Funding Ban on Planned Parenthood